Literature DB >> 34109098

Acute lymphoblastic leukemia-derived exosome inhibits cytotoxicity of natural killer cells by TGF-β signaling pathway.

Huijun Yu1,2, Tingting Huang2, Daming Wang2, Lei Chen2, Xi Lan2, Xintong Liu2, Keyan Chen2, Haihong He2, Shaobo Li2, Yiwen Zhou2, Jiansheng Xie1.   

Abstract

This study was conducted to explore whether acute lymphoblastic leukemia (ALL)-derived exosomes affect natural killer (NK) cells. Exosomes were isolated and identified from Jurkat cells and co-cultured with NK cells. Then, the cytotoxicity, viability, and release of perforin and granzyme B in NK92-MI cells were measured. PCR arrays were used to detect gene expression alterations in the transforming growth factor (TGF)-β pathway of NK92-MI cells treated or not treated with exosomes. The morphology and size of the exosomes isolated from Jurkat cells showed typical characteristics of exosomes, and the expression of cluster of differentiation 63 was detected. Jurkat-derived exosomes were internalized by NK92-MI cells, further inhibiting the proliferation and cytotoxicity of NK92-MI cells. An enzyme-linked immunosorbent assay revealed that the release of perforin and granzyme B from NK92-MI cells decreased after co-culture with exosomes. Similarly, western blot and immunofluorescence staining verified that Jurkat-derived exosomes inhibited the expression of granzyme B and perforin. Furthermore, Jurkat-derived exosomes enhanced the signaling of the TGF-β pathway in NK92-MI cells via the MDS1 and EVI1 complex loci and homeodomain interacting protein kinase 2. In conclusion, we found that ALL-derived exosomes inhibit the biological function of NK cells and provide support for the immunotherapy of ALL. © King Abdulaziz City for Science and Technology 2021.

Entities:  

Keywords:  Acute lymphoblastic leukemia; Cytotoxicity; Exosome; Natural killer; TGF-β signaling pathway

Year:  2021        PMID: 34109098      PMCID: PMC8178429          DOI: 10.1007/s13205-021-02817-5

Source DB:  PubMed          Journal:  3 Biotech        ISSN: 2190-5738            Impact factor:   2.893


  33 in total

1.  Acute lymphoblastic leukemia: an assessment of international incidence, survival, and disease burden.

Authors:  Aaron J Katz; Victoria M Chia; Wilma M Schoonen; Michael A Kelsh
Journal:  Cancer Causes Control       Date:  2015-09-16       Impact factor: 2.506

Review 2.  Eviction from the sanctuary: Development of targeted therapy against cell adhesion molecules in acute lymphoblastic leukemia.

Authors:  Sonali P Barwe; Anthony Quagliano; Anilkumar Gopalakrishnapillai
Journal:  Semin Oncol       Date:  2017-07-11       Impact factor: 4.929

3.  Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth.

Authors:  Sarah Oelsner; Anja Waldmann; Arne Billmeier; Jasmin Röder; Aline Lindner; Evelyn Ullrich; Rolf Marschalek; Gianpietro Dotti; Gundram Jung; Ludger Große-Hovest; Pranav Oberoi; Peter Bader; Winfried S Wels
Journal:  Int J Cancer       Date:  2019-03-24       Impact factor: 7.396

Review 4.  Acute lymphoblastic leukaemia.

Authors:  Hiroto Inaba; Mel Greaves; Charles G Mullighan
Journal:  Lancet       Date:  2013-03-22       Impact factor: 79.321

5.  Radiotherapy-induced overexpression of exosomal miRNA-378a-3p in cancer cells limits natural killer cells cytotoxicity.

Authors:  Joséphine Briand; Delphine Garnier; Arulraj Nadaradjane; Karen Clément-Colmou; Vincent Potiron; Stéphane Supiot; Gwenola Bougras-Cartron; Jean-Sébastien Frenel; Dominique Heymann; François M Vallette; Pierre-François Cartron
Journal:  Epigenomics       Date:  2020-04-08       Impact factor: 4.778

6.  miR-34c-5p promotes eradication of acute myeloid leukemia stem cells by inducing senescence through selective RAB27B targeting to inhibit exosome shedding.

Authors:  Danyue Peng; Huifang Wang; Lei Li; Xiao Ma; Ying Chen; Hao Zhou; Yi Luo; Yin Xiao; Lingbo Liu
Journal:  Leukemia       Date:  2018-02-02       Impact factor: 11.528

7.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

8.  Acute myeloid leukemia transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretion.

Authors:  B Kumar; M Garcia; L Weng; X Jung; J L Murakami; X Hu; T McDonald; A Lin; A R Kumar; D L DiGiusto; A S Stein; V A Pullarkat; S K Hui; N Carlesso; Y-H Kuo; R Bhatia; G Marcucci; C-C Chen
Journal:  Leukemia       Date:  2017-08-17       Impact factor: 11.528

9.  Counteracting the effect of leukemia exosomes by antiangiogenic gold nanoparticles.

Authors:  Catarina Roma-Rodrigues; Alexandra R Fernandes; Pedro V Baptista
Journal:  Int J Nanomedicine       Date:  2019-08-26

10.  Melanoma cell-derived exosomes in plasma of melanoma patients suppress functions of immune effector cells.

Authors:  Priyanka Sharma; Brenda Diergaarde; Soldano Ferrone; John M Kirkwood; Theresa L Whiteside
Journal:  Sci Rep       Date:  2020-01-09       Impact factor: 4.379

View more
  2 in total

Review 1.  Cancer exosomes and natural killer cells dysfunction: biological roles, clinical significance and implications for immunotherapy.

Authors:  Hamzeh Sarvnaz; Maedeh Arabpour; Samira Molaei Ramshe; Reza Hosseini; Leila Asef-Kabiri; Hassan Yousefi; Mohammad Esmaeil Akbari; Nahid Eskandari
Journal:  Mol Cancer       Date:  2022-01-14       Impact factor: 27.401

Review 2.  Emerging innovations on exosome-based onco-therapeutics.

Authors:  Xiaofeng Dai; Yongju Ye; Fule He
Journal:  Front Immunol       Date:  2022-08-31       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.